Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nicotine & cancer

This article was originally published in The Tan Sheet

Executive Summary

Transdermal and oral exposure to nicotine could contribute to cancer, researchers state in the January Journal of Clinical Investigation. Phillip Dennis, NCI, et al., find "sustained exposure to nicotine might alter the phenotype of endothelial and/or epithelial cells in undetectable, premalignant lesions," suggesting long-term exposure to smoking cessation drugs such as patches, gum could be harmful. NRT marketers Pharmacia, GSK point to lack of clinical evidence drugs cause cancer. "Tobacco dependence experts agree that the risks of developing cancer from short-term NRT use to aid smoking cessation are insignificant compared to the risks of developing cancer from cigarette smoking," Pharmacia states...

You may also be interested in...

Swiss Health Providers Turn Heat On Federal Council Fearing 12% Loss Of Medtech On EU MRA Failure

A consortium of Swiss providers, patient groups and health care trade bodies is imploring the federal council to avert a looming patient care crisis in Switzerland if the EU MRA cannot be agreed.

New China COVID Vaccine Arriving But COVAX Pledge May Need A Booster

China’s first domestically-developed recombinant protein vaccine for COVID-19 moves forward in late-stage trials in two countries.

QUOTED. 9 March 2021. Matthew Trerotola.

Splitting Colfax into separate fabrication technology and specialty medical technology businesses will help both sides of the business grow, CEO Matthew Trerotola said recently.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts